本文選題：脈管復(fù)康片 + 氣滯血瘀　； 參考：《黑龍江中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:觀察脈管復(fù)康片對(duì)多發(fā)性大動(dòng)脈炎患者的臨床療效。方法:選取黑龍江中醫(yī)藥大學(xué)附屬第一醫(yī)院周圍血管科2016年03月-2017年02月門診及病房收治的32例多發(fā)性大動(dòng)脈炎患者,隨機(jī)分為:治療組、對(duì)照組兩組,對(duì)照組16例給予一般治療。治療組16例在一般治療基礎(chǔ)上同時(shí)加服脈管復(fù)康片:一次4片,3次/d,治療療程為期1個(gè)月。治療前后進(jìn)行治療組及對(duì)照組的癥狀及實(shí)驗(yàn)室指標(biāo)(ESR、CRP)的比較。通過體征評(píng)分和治療情況進(jìn)行觀察和分析。結(jié)果:本實(shí)驗(yàn)所選取的多發(fā)性大動(dòng)脈炎32例患者,年齡平均(28.04±8.01)歲,最小14歲,最大39歲。其中男性6例,女性26例,男女比例1:4.3。經(jīng)過為期1個(gè)月的治療后,臨床觀察結(jié)果為:對(duì)照組:患者16例,治愈0例,顯效5例,有效7例,無效4例,總有效率75%;治療組:患者16例,治愈0例,顯效7例,有效9例,無效2例,總有效率87.5%。在觀察指標(biāo)方面,治療組治療C反應(yīng)蛋白、紅細(xì)胞沉降率,超聲下血管壁厚度和管壁狹窄程度經(jīng)統(tǒng)汁學(xué)分析,P0.05,有明顯性差異,說明脈管復(fù)康片對(duì)多發(fā)性大動(dòng)脈炎患者的治療顯著。在癥狀及體征評(píng)分方面,多發(fā)性大動(dòng)脈炎患者,經(jīng)過脈管復(fù)康片治療后,癥狀和體征總評(píng)分均下降明顯,患者頭暈、乏力、發(fā)熱、及頸部疼痛癥狀在治療前與治療后明顯緩解,頸動(dòng)脈雜音、搏動(dòng)及橈動(dòng)脈搏動(dòng)體征試驗(yàn)組及對(duì)照組比較則無明顯差異(P0.05)。說明脈管復(fù)康片治療多發(fā)性大動(dòng)脈炎患者的臨床癥狀及體征改善明顯,能夠提高患者生活質(zhì)量。結(jié)論:1.脈管復(fù)康片聯(lián)合丹參川芎嗪注射液和紅花黃色素氯化鈉注射液對(duì)對(duì)多發(fā)性大動(dòng)脈炎患者頸部動(dòng)脈血流有較明顯的改善。2.脈管復(fù)康片能夠降低ESR、CRP指標(biāo)的表達(dá)。3.脈管復(fù)康片聯(lián)合丹參川芎嗪注射液和紅花黃色素氯化鈉注射液對(duì)氣滯血瘀型多發(fā)性大動(dòng)脈炎患者臨床效果良好。
[Abstract]:Objective: to observe the clinical effect of Vascular Fukang tablet on patients with polyarteritis. Methods: Thirty-two patients with polyarteritis were randomly divided into two groups: treatment group and control group, from March 2016 to February 2017 in peripheral vascular department of the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine. In the control group, 16 cases were given general treatment. In the treatment group, 16 cases were treated with Vascular Fukang tablets on the basis of general treatment: 4 tablets per day, 3 times / d, for one month. The symptoms and laboratory indexes (ESR-CRP) of the treatment group and the control group were compared before and after treatment. Observation and analysis were carried out through physical sign score and treatment. Results: the average age of 32 patients with Takayasu arteritis was (28.04 鹵8.01) years old, the youngest was 14 years old and the oldest was 39 years old. There were 6 males and 26 females, and the ratio of males to females was 1: 4.3. After one month of treatment, the results of clinical observation were as follows: control group: 16 cases, cure 0 cases, remarkable effect 5 cases, effective 7 cases, ineffective 4 cases, total effective rate 750.The treatment group: 16 cases, cured 0 cases, remarkable effect 7 cases, treatment group: 16 cases, cured 0 cases, remarkable effect 7 cases, treatment group: 16 cases, cured 0 cases, remarkable effect 7 cases. The total effective rate was 87.5%. There were significant differences in C-reactive protein (CRP), erythrocyte sedimentation rate, thickness of vascular wall and stenosis degree of vessel wall under ultrasound in the treatment group (P 0.05). The treatment of Vascular Fukang tablets for patients with multiple arteritis is significant. In the aspect of symptom and sign score, the total score of symptoms and signs of patients with multiple arteritis after treatment with Vascular Fukang tablets decreased significantly. The symptoms of dizziness, fatigue, fever, and neck pain were obviously alleviated before and after treatment. There was no significant difference in carotid murmur pulsation and radial pulsation signs between the experimental group and the control group (P0.05). It indicated that the clinical symptoms and signs of the patients with multiple arteritis were improved obviously and the quality of life of the patients could be improved. Conclusion 1. Vascular Fukang tablets combined with salvia miltiorrhiza ligustrazine injection and safflower yellow sodium chloride injection can significantly improve the carotid artery blood flow in patients with multiple arteritis. Vascular Fukang tablets can reduce the expression of CRP. 3. Vascular Fukang tablets combined with salvia miltiorrhiza ligustrazine injection and safflower yellow sodium chloride injection had good clinical effect on patients with multiple arteritis with Qi stagnation and blood stasis.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R543.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 申國(guó)慶;龔春燕;孔麗娜;;脈管復(fù)康片致困倦和過敏反應(yīng)的中藥組分分析[J];藥學(xué)與臨床研究;2010年02期

2 崔朝兵;趙鋼;許志會(huì);黃艷紅;呂勃川;;脈管復(fù)康片治療下肢動(dòng)脈硬化閉塞癥的臨床觀察[J];中醫(yī)臨床研究;2012年07期

3 荀向紅;李小莉;;中醫(yī)藥綜合治療帶狀皰疹后神經(jīng)痛154例[J];中國(guó)城鄉(xiāng)企業(yè)衛(wèi)生;2013年05期

4 林釤;鄧躍毅;;脈管復(fù)康片治療3、4期慢性腎臟病的臨床觀察[J];中國(guó)中西醫(yī)結(jié)合腎病雜志;2014年01期

5 趙奇;栗力;史燕;;脈管復(fù)康片治療糖尿病合并下肢動(dòng)脈硬化閉塞癥介入術(shù)后療效觀察[J];實(shí)用中西醫(yī)結(jié)合臨床;2014年03期

6 劉媛媛;趙宇輝;王陽(yáng);張勇;;脈管復(fù)康片治療燒傷增生性瘢痕的臨床觀察[J];新中醫(yī);2014年07期

7 于海燕;陳大江;;脈管復(fù)康片中丹參酮的含量測(cè)定[J];黑龍江醫(yī)藥;2004年04期

8 ;標(biāo)準(zhǔn)修訂信息[J];中國(guó)藥品標(biāo)準(zhǔn);2003年02期

9 韓旭;蔣靖;;脈管復(fù)康片聯(lián)合青鵬軟膏治療限局性硬皮病療效觀察[J];山西中醫(yī);2013年01期

10 苗淑杰;熊英;趙洪瑾;;HPLC法測(cè)定脈管復(fù)康片中丹參酮Ⅱ_A的含量[J];天津藥學(xué);2006年02期

相關(guān)會(huì)議論文 前2條

1 李俊海;;脈管復(fù)康片治療下肢靜脈皮膚病變[A];2009全國(guó)中西醫(yī)結(jié)合周圍血管疾病學(xué)術(shù)交流會(huì)論文集[C];2009年

2 劉睿;鄧躍毅;;脈管復(fù)康片治療慢性腎臟病2-3期的臨床研究[A];第十一屆全國(guó)中西醫(yī)結(jié)合腎臟病學(xué)術(shù)會(huì)議論文匯編[C];2010年

相關(guān)重要報(bào)紙文章 前1條

1 李子云;中老年人應(yīng)防“下肢動(dòng)脈硬化閉塞癥”[N];家庭醫(yī)生報(bào);2007年

相關(guān)碩士學(xué)位論文 前1條

1 王東興;脈管復(fù)康片治療多發(fā)性大動(dòng)脈炎的臨床療效觀察[D];黑龍江中醫(yī)藥大學(xué);2017年

，

本文編號(hào)：2117083